aTyr Pharma, Inc. (ATYR)
Automate Your Wheel Strategy on ATYR
With Tiblio's Option Bot, you can configure your own wheel strategy including ATYR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATYR
- Rev/Share 0.002
- Book/Share 0.8259
- PB 0.9533
- Debt/Equity 0.154
- CurrentRatio 5.9328
- ROIC -0.8512
- MktCap 77144877.0
- FreeCF/Share -1.2558
- PFCF -0.6323
- PE -1.0182
- Debt/Assets 0.1159
- DivYield 0
- ROE -1.0011
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ATYR | RBC Capital Mkts | Outperform | Sector Perform | -- | $1.5 | Sept. 16, 2025 |
| Downgrade | ATYR | Leerink Partners | Outperform | Market Perform | -- | $1 | Sept. 15, 2025 |
| Downgrade | ATYR | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Sept. 15, 2025 |
| Downgrade | ATYR | H.C. Wainwright | Buy | Neutral | -- | -- | Sept. 15, 2025 |
| Downgrade | ATYR | Wells Fargo | Overweight | Equal Weight | -- | $1 | Sept. 15, 2025 |
| Initiation | ATYR | Leerink Partners | -- | Outperform | -- | $16 | Feb. 18, 2025 |
| Initiation | ATYR | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 6, 2025 |
| Initiation | ATYR | Wells Fargo | -- | Overweight | -- | $17 | Oct. 4, 2024 |
| Initiation | ATYR | Jefferies | -- | Buy | -- | $9 | Sept. 5, 2024 |
News
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 12, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 12, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ: ATYR). IF YOU SUFFERED A LOSS ON YOUR ATYR INVESTMENTS, CLICK HERE BEFORE DECEMBER 8, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
Investor Alert: Deadline Approaching to Join aTyr Pharma, Inc. (ATYR) Class Action - Contact Levi & Korsinsky
Published: November 11, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 11, 2025) - If you suffered a loss on your aTyr Pharma, Inc. (NASDAQ: ATYR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=176751&wire=5&utm_campaign=25 or contact Joseph E. Levi, Esq.
Read More
aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman
Published: November 11, 2025 by: PRNewsWire
Sentiment: Neutral
ATYR Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Nov. 11, 2025 /PRNewswire/ -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The firm urges investors in aTyr who suffered significant losses to submit your losses now.
Read More
ATYR Investor Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged – Hagens Berman
Published: November 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation.
Read More
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: November 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between November 7, 2024 and September 12, 2025, inclusive (the “Class Period”).
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman
Published: November 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The firm urges investors in aTyr who suffered significant losses to submit your losses now.
Read More
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between November 7, 2024 and September 12, 2025, inclusive (the “Class Period”).
Read More
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ATyr Pharma
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In ATyr To Contact Him Directly To Discuss Their Options
Read More
aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The new class action, King v.
Read More
ATYR INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ATYR To Contact Him Directly To Discuss Their Options
Published: November 03, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ATyr To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in ATyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ATyr Pharma, Inc. ("aTyr" …
Read More
ATYR Shareholder Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman
Published: October 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation.
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: October 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
Read More
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ATYR
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR).
Read More
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises aTyr Pharma, Inc., (“aTyr” or the "Company") (NASDAQ: ATYR) investors off a class action on behalf of investors that bought securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.
Read More
aTyr Pharma, Inc. (ATYR) Securities Class Action Filed; Class Period Significantly Enlarged -- Hagens Berman
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation.
Read More
Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact Levi & Korsinsky about pending Class Action - ATYR
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit.
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: October 28, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" or the …
Read More
ATYR Investor Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman
Published: October 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation.
Read More
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: October 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between November 7, 2024 and September 12, 2025, inclusive (the “Class Period”).
Read More
ATYR Investor Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman
Published: October 24, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Oct. 24, 2025 /PRNewswire/ -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. The new class action, King v.
Read More
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: October 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.
Read More
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: October 23, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming December 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR ATYR INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO.
Read More
ATYR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Published: October 23, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. ("aTyr" or the …
Read More
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors
Published: October 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises aTyr Pharma, Inc., (“aTyr” or the "Company") (NASDAQ: ATYR) investors off a class action on behalf of investors that bought securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to file a lead plaintiff motion.
Read More
About aTyr Pharma, Inc. (ATYR)
- IPO Date
- Website https://www.atyrpharma.com
- Industry Biotechnology
- CEO Sanjay S. Shukla
- Employees 56